Efavirenz conceptions in Soweto
5 October 2009. Related: Conference reports, Pregnancy.
2009
Impact of regimen and duration of therapy on risk of mother-to-child HIV transmission in Johannesburg
5 October 2009. Related: Conference reports, Pregnancy.
A cost-effectiveness analysis of the OCTANE trial
5 October 2009. Related: Conference reports, Pregnancy.
The PEARL study
5 October 2009. Related: Conference reports, Pregnancy.
Results from HSV-2 acyclovir studies
5 October 2009. Related: Conference reports.
Overview of TB-related studies at IAS
5 October 2009. Related: Conference reports, TB coinfection.
CD4 responses after viral suppression for more than 7 years on HAART
5 October 2009. Related: Antiretrovirals.
Raltegravir approved in Europe for treatment-naive patients
5 October 2009. Related: Antiretrovirals.
50mg and 100mg ritonavir doses achieve similar levels of saquinavir in Thai patients
5 October 2009. Related: Antiretrovirals.
Raltegravir trough levels reduced by etravirine may require use of TDM
2 October 2009. Related: PK and drug interactions.
Lopinavir/r affects PK exposure of some antimalarial drugs
2 October 2009. Related: PK and drug interactions.
Darunavir/r increases exposure to nevirapine
2 October 2009. Related: PK and drug interactions.
Interaction between Ginkgo biloba and efavirenz
2 October 2009. Related: PK and drug interactions.
Use of raltegravir in HIV-positive transplant recipients
2 October 2009. Related: PK and drug interactions.
Trends in Immunology: free access issue on immune senescence
2 October 2009. Related: Basic science and immunology.
Low viral loads in elite controllers
2 October 2009. Related: Basic science and immunology.
Immune surveillance below the radar: study offers explanation for acyclovir’s failure to reduce HIV risk
2 October 2009. Related: Basic science and immunology.
Low-level HIV replication versus latency: identifying the source of viral rebounds during treatment interruption
2 October 2009. Related: Basic science and immunology.
Detention and removal of HIV-positive people in the UK
2 October 2009. Related: BHIVA news.
Letter: comment on swine flu algorithm
2 October 2009. Related: Correspondence.
5th IAS Conference on HIV Pathogenesis, Treatment and Prevention abstracts
2 October 2009. Related: On the web.
Access to HCV treatment in Eastern Europe
2 October 2009. Related: On the web.
Guide to HIV and hepatitis B coinfection
2 October 2009. Related: On the web.
TAG pipeline report
2 October 2009. Related: On the web.
New TB website and resource
2 October 2009. Related: On the web.
Etravirine (Intelence) label change in the US due to severe hypersensitivity reactions
2 October 2009. Related: Antiretrovirals.
HIV and the kidneys
2 October 2009. Related: On the web.
Video news: online resource
2 October 2009. Related: On the web.
Volume 10 Number 9/10 September/October 2009 PDF
1 October 2009. Related: PDFs.
Volume 10 Number 7/8 July/August 2009
24 August 2009. Related: Editorial.
HIV swine flu triage tools and flowcharts
23 August 2009. Related: Special reports, Other news.
HIV and swine flu patient leaflet
23 August 2009. Related: Special reports, Other news.
5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-23 July 2009, Cape Town
23 August 2009. Related: Conference reports.
Five-year survival rates of 87% without routine CD4 or laboratory monitoring in DART study demonstrate an important model for ARV access programmes
23 August 2009. Related: Conference reports, Treatment access.
Biomarkers associated with mortality: long-term follow up from SMART
23 August 2009. Related: Conference reports.
Update on Interleukin-2 clinical trials
23 August 2009. Related: Conference reports.
Influenza vaccine effective in HIV-positive adults
23 August 2009. Related: Conference reports.
Reducing HIV transmission during breastfeeding
23 August 2009. Related: Conference reports, Pregnancy.
Treating children previously exposed to single dose nevirapine
23 August 2009. Related: Conference reports, Paediatric care.
10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam
23 August 2009. Related: Conference reports.
Monotherapy study may explain previous poor clinical results when abacavir and tenofovir are used in combination
23 August 2009. Related: Conference reports, PK and drug interactions.
Interactions between ARVs and antimalarials atovaquone and proguanil
23 August 2009. Related: Conference reports, PK and drug interactions.
Four weeks lopinavir/r to cover functional monotherapy when stopping HAART
23 August 2009. Related: Conference reports, Antiretrovirals.
Efavirenz-related studies: genetics, smoking and TDM
23 August 2009. Related: Conference reports, Antiretrovirals.
Atazanavir: a suitable case for TDM?
23 August 2009. Related: Conference reports, Antiretrovirals.
Raltegravir PK in blood plasma and the genital tract
23 August 2009. Related: Conference reports.
A CYP2B6 haplotype influences nevirapine plasma concentrations following a single dose to reduce mother to child transmission
23 August 2009. Related: Conference reports, Pregnancy.
Population pharmacokinetic model of nevirapine maternal to infant transfer through breastfeeding
23 August 2009. Related: Conference reports, Paediatric care.
Phenotypic and genotypic inhibitory quotients and virologic response in treatment experienced children
23 August 2009. Related: Conference reports, Paediatric care.
Tenofovir pharmacokinetics in three tenofovir-containing regimens in children and adolescents
23 August 2009. Related: Conference reports, Paediatric care.
Bioavailability of Thai generic lopinavir/ritonavir
23 August 2009. Related: Conference reports.
XVIII International Drug Resistance Workshop, 9-13 June 2009, Florida
22 August 2009. Related: Conference reports.
Transmitted multidrug-resistant HIV persists in PBMC DNA for years
22 August 2009. Related: Conference reports, Drug resistance.
Low-level Q148R in people without integrase inhibitor experience
22 August 2009. Related: Conference reports, Drug resistance.
Cut-offs suggested for predicting efavirenz failure with low-level K103N
22 August 2009. Related: Conference reports, Drug resistance.
Lower M184V rates with FTC/TDF than with 3TC/TDF
22 August 2009. Related: Conference reports, Drug resistance.
HBV resistance to lamivudine at undetectable and low levels of viremia
22 August 2009. Related: Conference reports, Hepatitis coinfection, Drug resistance.
Raltegravir approved in the US for treatment-naive patients: paranoia and anxiety added as side effects
22 August 2009. Related: Antiretrovirals.
UK (BHIVA) guidelines online for comment (2009)
22 August 2009. Related: Guidelines.
TMC207 reduces time to sputum conversion in phase II trial on patients with drug-resistant TB
22 August 2009. Related: TB coinfection.
Maximum suppression: ART intensification does not reduce residual viral load
22 August 2009. Related: Basic science and immunology.
The role of Ad5-specific CD4 T-cells in enhancing risk of HIV acquisition in the Merck vaccine trial
22 August 2009. Related: Basic science and immunology, Vaccines and microbicides.
Tracing HIV reservoirs
22 August 2009. Related: Basic science and immunology.
Illuminating early events in HIV infection using single genome amplification
22 August 2009. Related: Basic science and immunology.
Volume 10 Number 7/8 July/August 2009 PDF
1 August 2009. Related: PDFs.